Cannabis and Cancer at this US Federal Heath research agency

AIMS Co-Founder and Co-Director Dr Aggarwal served as an invited Guest Faculty in which he described his research and perspectives on the topic of Cannabis and Cancer at this US Federal Heath research agency.

Guest Faculty, National Cancer Institute/NIH, Cannabis and Cancer, Physician’s experience for NCI/NIH Complementary and Integrative Medicine Course, Spring term, 4/2/2020

https://nci.rev.vbrick.com/#/videos/7f4082e9-41d7-4ee7-8f7f-b1e80214ef5b

Comments from Dr. Aggarwal:

The video of a talk I did 9 months ago at the NIH/ National Cancer Institute posted this week. My talk goes from timestamp: 1:42-2:37

I was an invited Guest Faculty asked to describe my research and perspectives on the topic of Cannabis and Cancer at this US Federal Health research agency. It was an awesome opportunity to discuss the stigmatization and politicization within the health agencies themselves which contribute to health injustices and what can be done to remedy it. I got to share highlights of my work over the span of something like 18 years. Dr Jeff Hergenrather’s talk after mine is not to be missed. This was a pretty unique experience. As much of my training was funded by the NIH and I trained there for a year as well, this was my chance to report back, with senior scientists at NIDA, NCI, and NCCIH in the audience.

More on this series here: https://cam.cancer.gov/research/training_opportunities.htm

Latest Blog Posts

Stellate Ganglion Block Effectiveness for PTSD, Anxiety, and Depression in Psychiatric Outpatients: A Retrospective Analysis

Stellate Ganglion Block Effectiveness for PTSD, Anxiety, and Depression in Psychiatric Outpatients: A Retrospective Analysis

https://scholarworks.seattleu.edu/dnp-projects/166/ The prevalences of Post-Traumatic Stress Disorder (PTSD), generalized anxiety disorder (GAD), and major depressive disorder (MDD) have risen significantly in recent years, particularly following the COVID-19 pandemic. Many individuals remain symptomatic despite conventional treatments, highlighting the need for novel, integrative interventions. Stellate Ganglion Block (SGB), a procedure targeting the cervical sympathetic chain to modulate the autonomic nervous system, has emerged as a promising therapy for treatment-resistant psychiatric symptoms. Evaluating data from the PTSD Checklist for DSM-5 (PCL-5), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9), this retrospective study examined the clinical outcomes of PTSD, anxiety, and depression symptoms ...

Read More
BEWARE OF CANCER MISINFORMATION

BEWARE OF CANCER MISINFORMATION

Our AIMS Institute oncology team is well informed about alternative cancer therapies such as ivermectin, intravenous vitamin C, mistletoe, curcumin, and mebendazole.  We help our patients sort through marketing hype, wishful thinking, and the real value of some alternative treatments. We say to our cancer patients who do not trust conventional medicine to beware of misinformation on the internet.  Be discerning.  We can help. Here is a recent MEDSCAPE article on this topic. ...

Read More
AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

LJ STANDISH AND DAVID JAMES Dr. Standish and her team can help improve brain function, improve memory and slow cognitive decline in Alzheimer’s disease.  Please make an appointment to start.  Call 206-420-1321.  Scientific Rationale A protocol incorporating low-dose lithium orotate, Lion’s Mane mushroom extract, NADH, transcranial magnetic stimulation (TMS), and blood sugar regulation counseling is scientifically rational for treating cognitive decline based on mechanistic, preclinical, and emerging human studies. Low-Dose Lithium Orotate (5 mg/day) Recent brain tissue studies link low brain lithium to the onset and progression of Alzheimer’s disease, with deficiency accelerating synaptic loss and cognitive decline. Low-dose lithium orotate has ...

Read More
Call Us Text Us
Skip to content